DE Burlo Group Inc. Lowers Stock Holdings in STERIS plc (NYSE:STE)

DE Burlo Group Inc. lessened its holdings in STERIS plc (NYSE:STE) by 1.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 3,750 shares of the medical equipment provider’s stock after selling 50 shares during the quarter. DE Burlo Group Inc.’s holdings in STERIS were worth $910,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Ashton Thomas Securities LLC purchased a new stake in STERIS during the third quarter valued at approximately $25,000. Central Pacific Bank Trust Division purchased a new stake in STERIS during the third quarter valued at approximately $28,000. Quent Capital LLC lifted its position in STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 71 shares during the last quarter. Versant Capital Management Inc lifted its position in STERIS by 2,262.5% during the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 181 shares during the last quarter. Finally, Brown Brothers Harriman & Co. lifted its position in STERIS by 154.7% during the second quarter. Brown Brothers Harriman & Co. now owns 191 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 116 shares during the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on STE shares. JMP Securities restated a “market outperform” rating and set a $265.00 price target on shares of STERIS in a research note on Monday. KeyCorp increased their price objective on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and raised their price target for the company from $230.00 to $260.00 in a research report on Thursday, October 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a report on Friday, November 8th. Finally, Stephens reaffirmed an “overweight” rating and set a $260.00 price objective on shares of STERIS in a report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

Insider Transactions at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total value of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares in the company, valued at approximately $10,603,710. This represents a 35.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.14% of the company’s stock.

STERIS Stock Up 0.1 %

Shares of STERIS stock opened at $212.25 on Thursday. The company has a market capitalization of $20.95 billion, a P/E ratio of 48.46 and a beta of 0.85. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24. The company has a 50 day moving average of $228.50 and a 200 day moving average of $228.58.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $2.12 by $0.02. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a net margin of 8.02% and a return on equity of 13.78%. STERIS’s revenue for the quarter was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.03 EPS. As a group, research analysts forecast that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.07%. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.